Jun 8, 2022 8:30 am EDT SCYNEXIS Announces Submission of Supplemental New Drug Application of ibrexafungerp to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections
May 20, 2022 8:30 am EDT SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
May 12, 2022 7:00 am EDT SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 8:30 am EDT SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
May 5, 2022 8:30 am EDT SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
May 4, 2022 8:30 am EDT SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Apr 27, 2022 8:30 am EDT SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
Apr 26, 2022 5:18 pm EDT SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
Apr 22, 2022 8:15 am EDT SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
